Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.

Autor:	Cortes-Blanco A; Pharmacology and Clinical Evaluation Division, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain. Electronic address: acortesb_autonomo@aemps.es., Prieto-Yerro C; Pharmacology and Clinical Evaluation Division, Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain., Martinez-Lazaro R; Nuclear Medicine Department, idcsalud Hospital Albacete, Albacete, Spain., Zamora J; Clinical Biostatistics Department, Hospital Ramón y Cajal, Madrid, Spain., Jiménez-Huete A; Neurology Department, Hospital Ruber Internacional, Madrid, Spain., Haberkamp M; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany., Pohly J; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany., Enzmann H; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany., Zinserling J; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany., Strassmann V; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany., Broich K; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.
Jazyk:	angličtina
Zdroj:	Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2014 Oct; Vol. 10 (5 Suppl), pp. S395-9. Date of Electronic Publication: 2014 Jan 10.
DOI:	10.1016/j.jalz.2013.09.007
Abstrakt:	Florbetapir (18F) for brain amyloid positron emission tomography (PET) imaging has been recently approved in Europe to estimate β-amyloid neuritic plaque density in the brain when the subject is still alive. Such density is one of the key issues for the definitive diagnosis of Alzheimer's disease (AD) at autopsy. This capability of florbetapir (18F) is regarded as a significant improvement in the diagnostic procedures for adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive impairment. The current paper highlights the specific characteristics of the European marketing authorization of florbetapir (18F). (Copyright © 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu